Overview
U.S. hospital operator's Q1 revenue rose 7% yr/yr, beating analyst expectations
Q1 adjusted EBITDA increased 26% yr/yr and beat analyst expectations
Company says severe weather and lighter respiratory season weighed on admissions
Outlook
Ardent Health reaffirms 2026 full-year revenue guidance of $6.4 bln to $6.7 bln
Company expects 2026 adjusted EBITDA of $485 mln to $535 mln
Result Drivers
ADJUSTED ADMISSIONS GROWTH - 2% increase in adjusted admissions helped drive revenue growth, despite a 1.1% decline in admissions due to severe weather and a lighter respiratory season
HIGHER REVENUE PER ADMISSION - 5.5% increase in net patient service revenue per adjusted admission supported overall revenue growth
COST MANAGEMENT - Company cited effective cost management and IMPACT program savings, including lower salaries, wages and benefits (SWB) expense, as key drivers of adjusted EBITDA growth
Company press release: ID:nBwbymC4fa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$1.60 bln
$1.58 bln (10 Analysts)
Q1 EPS
$0.28
Q1 Net Income
$58.49 mln
Q1 Adjusted EBITDA
Beat
$124 mln
$107.79 mln (11 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Ardent Health Inc is $13.00, about 30.3% above its May 4 closing price of $9.98
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 6 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)